Supplementary Creatine as a Treatment for Gyrate Atrophy of the Choroid and Retina
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Gyrate atrophy of the choroid and retina is a disease characterized by progressive constriction of visual fields, a 10-fold to 20-fold elevation in plasma ornithine, and depressed activity of L-ornithine:2 oxoacid aminotransferase. Morphologically conspicuous but clinically unimportant atrophy of Type II muscle fibers progresses concomitantly with the eye disease. A pathogenic component of the disease may be deficient formation of creatine, caused by hyperornithinemia, which leads to a shortage of cellular phosphocreatine energy stores. To test the therapeutic value of replenishing the postulated deficiency of creatine, we supplemented the diet of seven patients with 1.5 g of creatine daily. During one year of this treatment the diameters of Type II muscle fibers increased from 34.1 +/- 7.1 to 49.9 +/- 7.0 micron (mean +/- S.D.) (P less than 0.001). There was no significant increase in the diameters of Type I fibers. The visual-field tests showed no further constriction during the therapy. Fundus photography revealed slow impairment at an age otherwise associated with rapid progression of the disease. These promising preliminary results need further evaluation with long-term follow-up studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, long-term, high dose ingestion of creatine (up to 30 g/d for up to 5 years) in patient populations has not been associated with an increased incidence of renal dysfunction [23, 155, 156, 172].”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [156]
In the citing paper
“Nor has the literature provided any support that creatine promotes renal dysfunction [22, 51, 85, 114, 156, 172, 243–248]”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [156]
In the citing paper
“Gyrate atrophy of the retina and choroid is another creatine deficiency disorder that is characterized as an enzymatic disorder attributable to defects in ornithine aminotransferase, resulting in elevated levels of ornithine, which negatively impacts creatine synthesis [57,67].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [57]
Citations
Cites
Muscle biopsy: A modern approach
(1975) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(75)90022-2 · Cited by 1,367
RAISED PLASMA-ORNITHINE AND GYRATE ATROPHY OF THE CHOROID AND RETINA
Simell, O., & Takki, K. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90667-3 · Cited by 251
Shih, V. E. (1969) · American Journal of Diseases of Children · doi:10.1001/archpedi.1969.02100030085009 · Cited by 159
Valle, D., Kaiser-Kupfer, M. I., & Valle, L. A. D. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.5159 · Cited by 146
Genetic aspects in gyrate atrophy of the choroid and retina with hyperornithinaemia.
Takki, K. K., & Simell, O. (1974) · British Journal of Ophthalmology · doi:10.1136/bjo.58.11.907 · Cited by 109
Valle, D. L., Walser, M., Brusilow, S. W., & Kaiser‐Kupfer, M. I. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109680 · Cited by 99
Gyrate atrophy of the choroid and retina with hyperornithinemia
Sipilä, I., Simell, O., Rapola, J., Sainio, K., & TUUTERI, L. (1979) · Neurology · doi:10.1212/wnl.29.7.996 · Cited by 90
Sipilä, I. (1980) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(80)90194-1 · Cited by 87
Ornithinemia, Hyperammonemia, and Homocitrullinuria
Fell, V. (1974) · American journal of diseases of children · doi:10.1001/archpedi.1974.02110240138023 · Cited by 67
Kaiser‐Kupfer, M. I., de Monasterio, F. M., Valle, D. L., Walser, M., & Brusilow, S. W. (1980) · Science · doi:10.1126/science.7444439 · Cited by 60
Cited by
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation
Harris, R. C., Söderlund, K., & Hultman, E. (1992) · Clinical Science · doi:10.1042/cs0830367 · Cited by 1,168
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057
“Moreover, long-term, high dose ingestion of creatine (up to 30 g/d for up to 5 years) in patient populations has not been associated with an increased incidence of renal dysfunction [23, 155, 156, 172].”
BackgroundMuscle creatine loading in men
Hultman, E., Soderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996) · Journal of Applied Physiology · doi:10.1152/jappl.1996.81.1.232 · Cited by 822
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
“Creatine is well tolerated in man, and is reported to be beneficial in several neurologic disease”
Background
Metadata
- Authors
- Sipilä, I., Rapola, J., Simell, O., & Vannas, A.
- Affiliations
- University of Helsinki (FI)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1981-04-09
- Volume
- 304
- Issue
- 15
- Pages
- 867-870
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2039564992
- Cited by
- 181
- References
- 14
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 3 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 1
- Type
- supplementary materials
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- gyrate atrophy of the choroid and retina, creatine supplementation, ornithine, hyperornithinemia, phosphocreatine, creatine deficiency, fast-twitch muscle, muscle fiber diameter, visual field constriction, disease progression
- MeSH terms
- Administration, Oral, Adolescent, Adult, Atrophy, Child, Choroid, Constriction, Pathologic, Creatine, Female, Fundus Oculi, Humans, Male, Muscular Atrophy, Ornithine, Ornithine-Oxo-Acid Transaminase, Photography, Retinal Diseases, Visual Acuity, Visual Fields
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Supplementary Creatine as a Treatment for Gyrate Atrophy of the Choroid and Retina. https://app.cochat.ai/papers/10.1056/nejm198104093041503
- The paper
- Sipilä, I., Rapola, J., Simell, O., & Vannas, A. (1981). Supplementary Creatine as a Treatment for Gyrate Atrophy of the Choroid and Retina. New England Journal of Medicine. https://doi.org/10.1056/nejm198104093041503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.